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Abstract
Anti-neutrophil cytoplasmantibody (ANCA)-associated vasculitis (AAV) is characterized bya variable disease course,with up to
50% of patients having one relapsewithin 5 years andmany progressing to end-stage organ damage despitemodern treatment
strategies. Moreover, complications arising from treatment dominate the causes of mortality andmorbidity both early and late
during disease, especially in the elderly and thosewith severe renal involvement, and there is additional uncertainty as to how
long treatment should be continued. There is, therefore, an urgent clinical need to identify robust biomarkers to better predict
treatment responses, risk of disease relapse and eventual complete clinical and immunological quiescence. To date, no such
biomarkers exist, but better understanding of diseasepathogenesis and theunderlying immunedysfunctionhasprovided some
potential candidates linked to the discovery of new antibodies, different leukocyte activation states, the role of the alternative
complement pathway andmarkers of vascular activation.With all promising new biomarkers, there is the need to rapidly replicate
and validate early ﬁndings using large biobanks of samples that could be brought together by leaders in the ﬁeld.
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Introduction
Anti-neutrophil cytoplasm antibody (ANCA)-associated vascu-
litis (AAV) comprises three different clinical entities: granuloma-
tosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and
eosinophilic granulomatosis with polyangiitis (EGPA). They are a
group of systemic diseases characterized by pauci-immune nec-
rotizing inﬂammation of small- to medium-sized blood vessels
and are differentiated by subtle differences in clinical phenotype.
AAV is deﬁned as a rare autoimmune disease with an incidence
of 20 patients per million/year [1]; however, recent reports sug-
gest this may be increasing [2].
Inmost patientswithGPAandMPA,ANCAs are detected andare
frequently directed against proteinase-3 (PR3) andmyeloperoxidase
(MPO), respectively, while only half of those patients with EGPA
have a detectable ANCA [3]. In addition, a signiﬁcant minority
of patients with limited GPA (often conﬁned to the upper respira-
tory tract) are ANCA negative, as are 5–10% of patients with focal
necrotizing, pauci-immune glomerulonephritis. Whether these
represent variants of AAV or have different aetiologies with simi-
lar ﬁnal pathologies is uncertain, but they appear to behave in
similar fashion to ANCA-positive disease. AAV affects multiple
organ systems, with renal (glomerulonephritis) and pulmonary
(haemorrhage, nodules, ﬁbrosis) involvement being themost fre-
quent and severe manifestations.
AAV is characterized by a variable disease course, which can
be limited and mild or systemic and life-threatening; with treat-
ment, it can recover and resolve leaving no permanent organ
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dysfunction or progress and lead to scarring and end-stage organ
damage. In conjunction with the short- and long-term toxicity of
current therapies, this makes optimal management of AAV pa-
tients a highly complex ﬁeld, which is often guided by phys-
ician-biased approaches rather than more objective approaches.
Customization of treatment is therefore highly desirable but is
limited by the lack ofmarkers signalling the likely outcome of dis-
ease. Tissue sampling to identify ongoing disease and differenti-
ate it from chronic damage may be helpful but is limited in its
use as a longitudinal marker. Kidney biopsies, for example, may
be biased by sampling error especially when considering focal
disease, and are invasive, making repeated assessments less
appealing. For this reason, there has been a longstanding search
for non-invasive biomarkers that can predict treatment responses
and disease relapses [4].
The aim of this review is to discuss some of the current and
potential future biomarkers in AAV and understand how they
are implicated in the pathogenesis of the disease (Table 1).
Current biomarkers
Inﬂammatorymarkers, suchas the erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP), are hampered by being non-
speciﬁc and therefore unable to differentiate infection from
disease, a common clinical dilemma. Similar to ANCA directed
against PR3 or MPO, these markers are helpful for diagnosis in
AAV, in conjunctionwith appropriate clinical andpathologicalﬁnd-
ings; however, they are less useful when assessing disease activity
in patients with an established diagnosis, or in predicting relapses.
ANCAs are important in the pathogenesis and diagnosis of
AAV; however, data supporting their utility as biomarkers of dis-
ease activity are less clear. Since a proportion of patients remain
ANCA positive despite clinical remission, the use of ANCA as
markers of disease remission or immunological quiescence is
limited. Early studies from single centres or small cohorts sug-
gested that in those who become ANCA negative during disease
remission, or in thosewith stable ANCA positivity, an increase in
titremay be used as amarker of pending disease relapse, in some
cases prompting change in management [5]. In 2006, a meta-
analysis of 22 studies on the value of ANCA measurements to
predict relapses concluded that no ﬁrm conclusions could be
drawn because of considerable methodological heterogeneity in
the different studies, such as differences of follow-up time and
time between serial ANCA measurements, variations in deﬁn-
ition of remission and relapse, different techniques for ANCA
measurement and different deﬁnitions of a rising titre [6]. In an-
other meta-analysis [7], Tomasson et al. evaluated nine studies
and found that both rising ANCA or persistently positive ANCA
were poorly associated with ﬂares (positive likelihood ratio 2.84
and 1.97, with a sensitivity of 0.56 and 0.38; speciﬁcity 0.82 and
0.78, respectively). In contrast, Kemna et al. [8] noted that longitu-
dinal ANCAmeasurements may be useful in a subset of patients
with renal involvement. They found that rising ANCA titres were
signiﬁcantly correlated with relapses in patients with renal dis-
ease (hazard ratio: 11.09), whereas this association was less
clear-cut in those subjects without overt renal disease (hazard
ratio: 2.79). However, less than half of the patients with a rising
ANCA titre experienced a relapsewithin a year,making it difﬁcult
to use these data as ameans of pre-emptively treating patients to
prevent disease relapse.
Taken together, persistent ANCA or a rising titre seems insuf-
ﬁcient to change treatment decisions. However, in patients with
AAV and renal involvement, an increase in ANCA titre could be
used as a rationale to more carefully follow these patients, mon-
itoring for other earlier signs of disease ﬂare.
Another important issue about ANCA as a biomarker was the
presence of AAV patients with negative ANCA, presenting an im-
portant challenge regarding the pathogenic role of this antibody.
To address this issue, Roth et al. developed an epitope mapping of
murine and humanMPO-ANCA and revealed that this antibody in
ANCA-negative disease reacted against a sole linear sequence and
wascapable of in vitroneutrophil activationand inductionnephritis
in mice. This important discovery could provide a better under-
standing of the evolution of the disease and enhance the ability
to identify at-risk individuals prior to disease development [9].
New biomarkers in AAV
Other antibodies
It is possible that additional humoral mediators, other than the
classical ANCA, are involved in development of AAV in patients,
and may serve as markers of disease activity. There are a number
of other, recently described, autoantibodies, suchas those directed
at lysosome-associated membrane protein-2 (LAMP-2), moesin,
Table 1. Summary of biomarkers in AAV
Biomarker Comment
Inﬂammatory markers Non-speciﬁc. Unable to differentiate infection from disease.
ANCA Persistent ANCA or rising titre insufﬁcient to change treatment decisions. More useful in patients with renal disease.
LAM-2 antibodies (Ab) Titres fall rapidly after treatment and recur in relapse. Need standardized techniques.
Moesin Ab Associated with more renal damage. No data on disease relapse. Not replicated outside Japan.
Plasminogen Ab Mostly found in active disease. Correlates with glomerular lesion severity. No data on disease relapse.
Pentraxin-3 Ab Mostly found in active disease. No data on disease relapse.
Bregs Contradictory data in active and remission. No data on disease relapse. Need a homogenous marker and functional
assays.
T cells CD8+ proﬁle: able to identify patients more likely to relapse. Must do a prospective validation.
Granulocytes subsets Treatment with RTX: better response in patients with higher GI, versus CYC: better response with a lower GI.
Complement Higher levels in active compared with remission disease. Results need to be replicated in larger studies.
Calprotectin Failure to decrease serum calprotectin by Month 2 or 6 compared with baseline: higher relapse risk in PR3-ANCA
treated with RTX.
Urine MCP-1 Higher levels associated with relapse and poor prognosis.
Urine-soluble CD163 Higher levels in active renal disease compared with remission.
RTX, rituximab; CYC, cyclophosphamide; GI, granularity index.
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plasminogen and pentraxin-3 that have been found in AAV
patients.
Autoantibodies to LAMP-2 are co-expressed with ANCA direc-
ted against MPO or PR3 in patients with pauci-immune glomer-
ulonephritis but have also been found in ANCA-negative cases.
LAMP-2 is expressed in neutrophils and in endothelial cells.
Autoantibodies to LAMP-2 have been described in 80–90% of pa-
tients presenting with AAV, become rapidly undetectable after
the start of immunosuppressive treatment, are rare in patients
during disease remission, but recur in thosewith clinical relapses
[10, 11]. However, a lower frequency of antibodies has been re-
ported by other investigators, who found anti-LAMP-2 antibodies
in only 21% of AAV patients compared with 16% of controls. In
addition, the assays for their detection have not been standar-
dized or made widely available. These conﬂicting results make
the value of currently using this antibody as a biomarker of dis-
ease activity unlikely [12].
Moesin is a member of the ezrin family of proteins that link
actin to the plasmamembrane. Anti-moesin antibodies were ori-
ginally described in serum from SCG/Kj mice that spontaneously
develop vasculitis. More recently, a cross-sectional study of 60
Japanese patients with MPO-AAV found that anti-moesin anti-
bodies were present in the serum of half of the cohort. The
anti-moesin antibodies were detected in both active disease
and remission, but were associated with more renal damage (as
assessed by levels of blood urea nitrogen, serum creatinine and
proteinuria). Interestingly, the autoantibodies bound to moesin
in neutrophils and monocytes result in a cytoplasmic ANCA pat-
tern on indirect immunoﬂuorescence. However, testing for the
presence of the antibody in non-Japanese populations has not
been carried out, nor has their presence been correlatedwith sus-
ceptibility for relapse [13].
Plasminogen is a key protein in the ﬁbrinolysis system, and
antibodies directed to it were found in 24 and 26% of AAVpatients
from UK and Dutch cohorts (compared with 2% of healthy
controls) [14]. The presence of antibody correlated with in vitro
prolongation of ﬁbrinolysis in a proportion of patients, and with
glomerular lesion severity. Similar ﬁndings were reported in a
Chinese cohort of 104 AAV patients, in whom anti-plasminogen
antibodies were present in 18% of patients with active disease
and only 2% of those in remission. Weak correlations were
found between antibody titre and ESR, renal function and certain
renal biopsy features [15].
Pentraxin-3 [16] is stored in neutrophil granules and is ex-
pressed on the surface of apoptotic neutrophils. Antibodies to
pentraxin-3 were measured in 150 AAV patients and various
healthy or disease controls. They were found in the sera of 37%
of AAV patients (compared with 5.3% of healthy controls and
7.5% of scleroderma patients), and in up to 50% of ANCA-negative
AAV. Levels were higher in patientswith active disease compared
with those in remission, but considerable overlap was found. No
data on disease relapse were provided. These antibodies may be
useful inmaking a diagnosis of disease in a subset of patients, but
their signiﬁcance and correlationwith disease activity haveyet to
be validated and may be no better than ANCA itself.
Taken together, these novel autoantibodies appear in only a
proportion of patients and may serve to identify a subset with
more severe disease features, which may be useful in customiz-
ing therapy for those with a worse phenotype. None of the stud-
ies has investigated the impact of these antibodies for predicting
relapse or compared them with change in ANCA titre. Few of
them of have been validated in larger independent cohorts,
which is obviously the next critical step in understanding their
signiﬁcance and utility.
Leukocyte subsets
The importance of B lymphocytes in the pathogenesis of AAV
was conﬁrmed through the clinical efﬁcacy of B-cell-target ther-
apy. In the RAVE and RITUXIVAS studies, rituximab (RTX) was de-
monstrated to be non-inferior to cyclophosphamide (CYC) for
induction of remission in severe AAV [17, 18].
B lymphocytes can be further classiﬁed according to function
and expression of certain markers, dividing them into memory
cells, regulatory cells, mature cells and plasmablasts. B subsets,
particularly regulatory B-cells (Bregs), have been investigated as
potential biomarkers in AAV since they are implicated in inhibit-
ing autoimmune disease. One critical issue is that different
groups use different markers to deﬁne Bregs, with few using
functional assays of suppression to conﬁrm their regulatory
phenotype. Eriksson et al. [19] found CD25+ B cells to be increased
in clinical remission relative to acute disease. Bunch et al. [20] de-
scribed a numerical deﬁciency in CD5+ B cells in AAV patients
compared with controls, which wasmost profound during active
disease. In contrast, the RAVE group measured the absolute
and relative number of CD5+ B cells longitudinally in their trial
participants [21]. After an initial decline, absolute CD5+ B cell
numbers progressively increased in patients in the RTX arm,
but remained low in patients in the CYC arm. Interestingly,
during relapse the percentage of CD5+ B cells correlated inversely
with disease activity only in RTX-treated patients, but the
dynamics of CD5+ cells did not predict disease relapse. Todd
et al. [22] found a numerical, but not functional, deﬁciency in
Breg deﬁned as CD24hiCD38hi B cells during disease remission
in PR3- and MPO-AAV patients, while the frequency of memory
cells (CD24hiCd38lo) was reduced in active disease and restored
during remission. However, no correlation with disease relapse
was investigated. In summary, Bregs do not, at present, seem a
good biomarker for relapse, but standardization of staining and
gating strategies with validation in different cohorts may allow
more consistent ﬁndings and conclusions to be made.
T cells are also involved in the pathogenesis of AAV, being
abundantly present in inﬂammatory lesions, and have the poten-
tial to destroy tissue integrity by driving granuloma formation (in
GPA and EGPA), by cytokine production or by direct effect on endo-
thelial cells [23], being the predominant cells in inﬂammatory tis-
sue inﬁltrates. The most promising study related to T cells in AAV
was published in 2010. McKinney et al. demonstrated that a par-
ticular gene expression signature seen in CD8+T cells, markers re-
lated to T cell survival and memory T cell, showed a strong
association with subsequent disease relapse [24]. If this ﬁnding is
validated in prospective studies and if it can be adapted into a clin-
ically viable test, then it couldhelp identifya groupofpatientswith
greater propensity for relapse, allowing customization of therapy.
Recently,Nasrallah et al. identiﬁed distinct subsets of granulo-
cytes in patients that participated in the RAVE study, based on
granularity index (GI), which measures the difference between
the percentage of hypergranular and hypogranular granulocytes.
They found that RTX-treated patients who achieved remission
had a signiﬁcantly higher GI at baseline than those who did not
(P = 0.0085) and that this pattern was reversed in CYC-treated pa-
tients (P = 0.037). These different granulocyte proﬁles could be in-
teresting for identifying the patients who best respond to these
different therapeutic strategies in AAV [25].
Markers of vascular activation
Complement. In animal models, alternative complement activa-
tion has been implicated in pathogenesis of AAV [26], and in
Biomarkers in ANCA-associated vasculitis | 549
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recent work, Xiao et al. proved that blockade of C5a receptor
(C5aR) in transgenic mice expressing human C5aR protected
against disease activity [27].
Following these discoveries, Gou et al. showed that plasma le-
vels of C3a, C5a, soluble C5b–9 and Bbwere increased in 66 patients
with active AAV compared with 54 patients in remission [28]. The
samegroupalso foundapositive correlationbetweenurinary levels
of Bb with serum creatinine in patients with active disease and an
inverse correlation with the percentage of normal glomeruli in the
renal biopsy [29]. These are small studies and the use of comple-
ment components as biomarkers in AAV must be evaluated
among larger cohorts and in those with non-renal disease. In par-
ticular, prospective studies looking at these markers in renal biop-
sies or in serum need to be carried out to validate these markers.
Toll-like receptor-4 and receptor for advanced glycation end-products.
The link between infection andAAV iswell established. In animal
models, toll-like receptor-4 (TLR4) ligation is involved in disease
induction [30]. A recent publication [31] demonstrated that high-
mobility group box-1 (HMGB1), a typical damage-associated mo-
lecular pattern (DAMP) protein associated with inﬂammatory
conditions and tissue damage, is able to prime neutrophils by in-
creasing ANCA antigen translocation, and the primed neutro-
phils could be further activated by ANCA, resulting in the
respiratory burst and degranulation. This process is dependent
on TLR4 and receptor for advanced glycation end-products
(RAGE) through the MyD88/NF-κB pathway. Along similar lines,
calprotectin (S100A8/S100A9), a calcium-binding protein found
abundantly in neutrophils, monocytes and early-differentiated
macrophages, and an endogenous ligand of TL4 and RAGE
showed interesting results [32–34]. Calprotectin has been
shown to be upregulated in many inﬂammatory disorders, in-
cluding AAV [35–38]. During remission in patients with limited
systemic AAV, Pepper et al. [39] showed that calprotectin levels in-
creased in those who developed a future relapse compared with
those who did not, making calprotectin a possible useful bio-
marker to predict relapses. More recently, analysing 144 patients
enrolled in the RAVE trial, it was shown that failure to decrease
serum calprotectin byMonth 2 or 6 comparedwith baseline iden-
tiﬁed a subgroup of PR3-ANCA patients treated with RTX at high-
er risk of subsequent relapse.
Panel of biomarkers
Recent studies have tested numerous biomarkers to identify
promising tools to identify predictors of treatment response
and relapse in patients with AAV.
The most robust study [40] tested 28 markers of inﬂammation,
angiogenesis, tissue damage and repair in 186 patients enrolled in
the RAVE study, before and 6 months after treatment in order to
distinguish active disease from remission. They identiﬁed three
promisingbiomarkers (MMP-3, TIMP-1 andCXCL13) that best discri-
minated these two conditions. Follow-up studies on clinical rele-
vant endpoints for the prediction of relapse rates, are needed.
Urinary biomarkers
Urine sediment analysis and proteinuria could be helpful in de-
tecting early relapse in AAV with renal involvement. However,
this biomarker is non-speciﬁc; proteinuria may also indicate
renal ﬁbrosis and haematuria can persist for months or years
despite clinical remission [41, 42]. However, two urinary biomar-
kers showed promising results in AAV as predictors of disease
activity.
Monocyte-chemoattractant protein-1 (MCP-1), a chemokine
that promotes monocyte recruitment to areas of inﬂammation,
has been shown to be increased in AAV patients in active disease
compared with other forms of glomerulonephritis with a speciﬁ-
city of 94% and a sensitivity of 89% (AUC 0.93, positive likehood
ratio: 8.5 and negative likehood ratio: 0.07), and elevated levels
were associated with poor prognosis and relapse [43, 44].
Recently, O’Reilly et al. demonstrated that urinary-soluble
CD163, shed by monocytes and macrophages, was markedly
higher in patients with active disease compared with patients
in remission in a cohort of 177 patients with AAV. With a cut-
off of 0.3 ng/mmol creatinine, they found a sensitivity of 83%
and a speciﬁcity of 96% (positive likehood ratio of 20.8) for detec-
tion of active renal vasculitis [45].
These two biomarkers could have an interesting use for diag-
nosing renal ﬂare in AAV and to triage patients with undifferen-
tiated acute kidney injury, when serologic markers or histologic
samples are delayed.
Conclusions
Numerous studies of potential biomarkers in AAV comparing ac-
tive diseasewith disease remission have been reported. However,
clinically useful biomarkers for prediction of relapse and re-
sponse are still required for better management of patients
with AAV. Many of the recent discoveries described in this review
require validation in separate cohorts. As new insights into the
pathogenesis of AAV emerge, so too new markers and therapies
will help guide disease therapy.
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